Cathy Kelly
Senior Writer
Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
Updated interchangeability guidance is one of several 'incremental reforms' agency is working on that could ease development burden for biosimilars, Commissioner Scott Gottlieb says.
Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says
Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.
PBMs Offering Prescribers Real Time Visibility On Cost-Sharing, Cheaper Alternatives
CVS Health and OptumRx join Express Scripts in offering programs to enhance transparency around prescription drug cost sharing, reinforcing the impact of formulary placement.
Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies
No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.
ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
Institute for Clinical and Economic Review launching pilot program that allows drug assessment models to be inspected, but not manipulated, by manufacturers.
Advertisement